Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
出版年份 2022 全文链接
标题
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
作者
关键词
-
出版物
ANNALS OF THE RHEUMATIC DISEASES
Volume 82, Issue 1, Pages 107-118
出版商
BMJ
发表日期
2022-11-15
DOI
10.1136/ard-2022-223357
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials
- (2022) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
- (2022) Farzin Khosrow-Khavar et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)
- (2022) Markus Bredemeier et al. JOURNAL OF RHEUMATOLOGY
- Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
- (2022) Steven R. Ytterberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- AB1008 CHARACTERIZATION OF THE RISK OF OSTEOPOROSIS IN A COHORT OF RHEUMATIC PATIENTS DURING 10 YEARS OF FOLLOW-UP.
- (2022) L. Dulcey et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2022) Sytske Anne Bergstra et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial
- (2021) René Westhovens et al. ANNALS OF THE RHEUMATIC DISEASES
- Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
- (2021) Bernard Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study
- (2021) Kosuke Ebina et al. CLINICAL RHEUMATOLOGY
- Safety and Efficacy of Filgotinib: Up to 4-Year Results From an Open-Label Extension Study of Phase 2 Rheumatoid Arthritis Programs
- (2021) Arthur Kavanaugh et al. JOURNAL OF RHEUMATOLOGY
- Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan
- (2021) Tsutomu Takeuchi et al. Rheumatology and Therapy
- Effects of denosumab in Japanese rheumatoid arthritis patients treated with conventional anti-rheumatic drugs: 36-month extension of a phase 3 study
- (2021) Yoshiya Tanaka et al. JOURNAL OF RHEUMATOLOGY
- Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study
- (2021) Rishi J Desai et al. RHEUMATOLOGY
- Risk of Diverticulitis and Gastrointestinal Perforation in Rheumatoid Arthritis Treated with Tocilizumab Compared to Rituximab or Abatacept
- (2021) Claire Rempenault et al. RHEUMATOLOGY
- Long-term safety and efficacy of sarilumab over 5 years in patients with rheumatoid arthritis refractory to TNF inhibitors
- (2021) Roy Fleischmann et al. RHEUMATOLOGY
- Non‐serious infections in patients with rheumatoid arthritis; results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
- (2021) Katie Bechman et al. Arthritis & Rheumatology
- Cardiovascular Safety of Hydroxychloroquine in Veterans with Rheumatoid Arthritis
- (2021) Charles Faselis et al. Arthritis & Rheumatology
- Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis
- (2021) Thomas R.P. Taylor et al. Neurology-Neuroimmunology & Neuroinflammation
- AB0723 JUVENILE BEHCET’S DISEASE: WHICH PARTICULARITIES?
- (2021) O. Jomaa et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register
- (2021) Imke Redeker et al. ANNALS OF THE RHEUMATIC DISEASES
- Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study
- (2021) Evgeniy Nasonov et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Heart Failure in Rheumatoid Arthritis Patients Treated with Tumour Necrosis Factor‐α Inhibitors
- (2021) Hung‐Kai Chen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Association of Hospitalised Infection With Socioeconomic Status in Patients With Rheumatoid Arthritis Receiving Biologics or Tofacitinib: A Population-Based Cohort Study
- (2021) Hsin-Hua Chen et al. Frontiers in Medicine
- Long-term safety and efficacy of olokizumab in patients with rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitor therapy in phase II studies
- (2021) Mark C. Genovese et al. European Journal of Rheumatology
- Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations
- (2021) Féline P B Kroon et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
- (2021) Peter C Taylor et al. ANNALS OF THE RHEUMATIC DISEASES
- Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
- (2021) Kevin L Winthrop et al. ANNALS OF THE RHEUMATIC DISEASES
- Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study
- (2021) Shin-ichiro Ohmura et al. INTERNAL MEDICINE
- All-cause and cause-specific mortality of patients with rheumatoid arthritis in Korea: A nation-wide population-based study
- (2021) Eunyoung Emily Lee et al. JOINT BONE SPINE
- Characteristics, Comorbidities, and Outcomes of SARS-CoV-2 Infection in Patients With Autoimmune Conditions Treated With Systemic Therapies: A Population-based Study
- (2021) Jeffrey R. Curtis et al. JOURNAL OF RHEUMATOLOGY
- Pregnancy outcomes in relation to disease activity and anti-rheumatic treatment strategies in women with rheumatoid arthritis: a matched cohort study from Sweden and Denmark
- (2021) Karin Hellgren et al. RHEUMATOLOGY
- Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States
- (2021) Rahul Raiker et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea
- (2021) Ha-Lim Jeon et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Risk of venous thromboembolism associated with methotrexate versus hydroxychloroquine for rheumatoid arthritis: A propensity score-matched cohort study
- (2021) Mengdong He et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision
- (2021) Hannah Bower et al. RMD Open
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
- (2020) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
- (2020) Andreas Kerschbaumer et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2020) Alexandre Sepriano et al. ANNALS OF THE RHEUMATIC DISEASES
- Biological agents reduce cardiovascular events in rheumatoid arthritis non-responsive to tumor necrosis factor-inhibitors – a national cohort study
- (2020) Ming-Jer Hsieh et al. CANADIAN JOURNAL OF CARDIOLOGY
- Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
- (2020) Ziga Rotar et al. BMJ Open
- Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden
- (2020) Tine Iskov Kopp et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study
- (2020) Hideto Kameda et al. RHEUMATOLOGY
- Discontinuation of Biologic Therapy due to Lack/loss of Response and Adverse Events is Similar Between TNFi and non-TNFi Class: Results from a Real-World Rheumatoid Arthritis Cohort
- (2020) Mohammad Movahedi et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial
- (2020) Ronald van Vollenhoven et al. Arthritis & Rheumatology
- The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis
- (2020) Gulsen Ozen et al. JOURNAL OF RHEUMATOLOGY
- Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
- (2020) Andrea Rubbert-Roth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs—a Swedish cohort study of risks by time, drug and lymphoma subtype
- (2020) Karin Hellgren et al. RHEUMATOLOGY
- Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study
- (2019) Jacques-Eric Gottenberg et al. BMJ-British Medical Journal
- Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: a multi-database cohort study
- (2019) Seoyoung C. Kim et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Abatacept initiation in rheumatoid arthritis and the risk of serious infection: A population-based cohort study
- (2019) François Montastruc et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial
- (2019) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis
- (2019) Yoshiya Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR
- (2019) Roberto Ranza et al. CLINICAL RHEUMATOLOGY
- Effect of Concomitant Disease-modifying Antirheumatic Drugs and Methotrexate Administration Route on Biologic Treatment Durability in Rheumatoid Arthritis: OBRI Cohort Results
- (2019) Arthur N. Lau et al. JOURNAL OF RHEUMATOLOGY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
- (2019) Roy M Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy
- (2019) Mark C. Genovese et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)
- (2019) Hideto Kameda et al. Modern Rheumatology
- Efficacy and safety of long-term baricitinib with and without methotrexate for the treatment of rheumatoid arthritis: experience with baricitinib monotherapy continuation or after switching from methotrexate monotherapy or baricitinib plus methotrexate
- (2019) Roy Fleischmann et al. ARTHRITIS CARE & RESEARCH
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Risk of serious infection among initiators of TNF inhibitors plus methotrexate versus triple therapy for rheumatoid arthritis: a cohort study
- (2019) Eun Ha Kang et al. ARTHRITIS CARE & RESEARCH
- Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial
- (2019) Jon T. Giles et al. Arthritis & Rheumatology
- Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study
- (2019) Kathrine L Grøn et al. RHEUMATOLOGY
- Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study
- (2019) Sibylle de Germay et al. RHEUMATOLOGY
- Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
- (2018) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients
- (2018) Fenglong Xie et al. ARTHRITIS CARE & RESEARCH
- Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study
- (2018) François Montastruc et al. RHEUMATOLOGY
- Risk of Hospitalized Infection and Initiation of Abatacept versus TNF Inhibitors among Patients with Rheumatoid Arthritis: a Propensity Score-Matched Cohort Study
- (2018) Sarah K. Chen et al. ARTHRITIS CARE & RESEARCH
- Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate
- (2018) Jeffrey R Curtis et al. ARTHRITIS CARE & RESEARCH
- Risk of malignancy in patients with rheumatoid arthritis after anti-tumor necrosis factor therapy: results from Korean National Health Insurance claims data
- (2017) Seung Min Jung et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- (2016) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
- (2015) Camille Roubille et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study
- (2014) Alexis Ogdie et al. ANNALS OF THE RHEUMATIC DISEASES
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
- (2012) Juan Antonio Avina-Zubieta et al. ANNALS OF THE RHEUMATIC DISEASES
- Editorial: Methotrexate saves lives: A pearl of observational research
- (2012) Robert B. M. Landewé ARTHRITIS AND RHEUMATISM
- Systematic review and meta-analysis: Anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis
- (2010) Cheryl Barnabe et al. ARTHRITIS CARE & RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now